The potential for physicians to favor innovator biologics over follow-on biologics because of a reimbursement advantage would be eliminated under an amendment to health care reform legislation adopted by the Senate Finance Committee Sept. 23

Rep. Henry Waxman, D-Calif., can perhaps take some comfort in the fact that his defeat on follow-on biologics means his broader health reform legislation may have a greater chance of passage

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.